Itama Ranoraya
PT Itama Ranoraya Tbk wholesale trades in laboratory and pharmaceutical equipment, and medical devices for humans in Indonesia. The company offers in vitro diagnostics products comprising rapid test and clinical laboratory; medical imaging products, including bone densitometer, C-arm, flat panel digital detector, mobile and stationary x-ray, and mammography; cardiovascular, urology, and surgical … Read more
Itama Ranoraya (IRRA) - Net Assets
Latest net assets as of September 2025: Rp556.81 Billion IDR
Based on the latest financial reports, Itama Ranoraya (IRRA) has net assets worth Rp556.81 Billion IDR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rp2.72 Trillion) and total liabilities (Rp2.16 Trillion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rp556.81 Billion |
| % of Total Assets | 20.46% |
| Annual Growth Rate | 62.04% |
| 5-Year Change | 111.41% |
| 10-Year Change | N/A |
| Growth Volatility | 116.68 |
Itama Ranoraya - Net Assets Trend (2016–2024)
This chart illustrates how Itama Ranoraya's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Itama Ranoraya (2016–2024)
The table below shows the annual net assets of Itama Ranoraya from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Rp512.31 Billion | +11.57% |
| 2023-12-31 | Rp459.20 Billion | -5.13% |
| 2022-12-31 | Rp484.04 Billion | -3.59% |
| 2021-12-31 | Rp502.05 Billion | +107.18% |
| 2020-12-31 | Rp242.33 Billion | +3.05% |
| 2019-12-31 | Rp235.17 Billion | +252.88% |
| 2018-12-31 | Rp66.64 Billion | +50.27% |
| 2017-12-31 | Rp44.35 Billion | +311.36% |
| 2016-12-31 | Rp10.78 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Itama Ranoraya's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 89251.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rp249.66 Billion | 48.73% |
| Common Stock | Rp75.39 Billion | 14.72% |
| Other Comprehensive Income | Rp-652.95 Million | -0.13% |
| Other Components | Rp187.91 Billion | 36.68% |
| Total Equity | Rp512.31 Billion | 100.00% |
Itama Ranoraya Competitors by Market Cap
The table below lists competitors of Itama Ranoraya ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
RGT Bhd
KLSE:9954
|
$4.90 Million |
|
LIVEONE INC. DL-001
F:3510
|
$4.90 Million |
|
BIO PLANET S.A. ZY 1
F:8WS
|
$4.90 Million |
|
Electricite et Eaux de Madagascar SA
PA:EEM
|
$4.90 Million |
|
Softcen Co. Ltd
KQ:032680
|
$4.89 Million |
|
Jayjun Co Ltd
KO:025620
|
$4.89 Million |
|
LSIS Co. Ltd.
KQ:010120
|
$4.89 Million |
|
Urgent.ly Inc. Common Stock
NASDAQ:ULY
|
$4.89 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Itama Ranoraya's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 459,201,214,256 to 512,312,964,000, a change of 53,111,749,744 (11.6%).
- Net income of 53,263,191,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 151,441,340.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rp53.26 Billion | +10.4% |
| Other Comprehensive Income | Rp-151.44 Million | -0.03% |
| Other Changes | Rp84.00 | +0.0% |
| Total Change | Rp- | 11.57% |
Book Value vs Market Value Analysis
This analysis compares Itama Ranoraya's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.15x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 57.88x to 1.15x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | Rp6.74 | Rp390.00 | x |
| 2017-12-31 | Rp27.72 | Rp390.00 | x |
| 2018-12-31 | Rp41.65 | Rp390.00 | x |
| 2019-12-31 | Rp146.98 | Rp390.00 | x |
| 2020-12-31 | Rp159.32 | Rp390.00 | x |
| 2021-12-31 | Rp326.78 | Rp390.00 | x |
| 2022-12-31 | Rp309.34 | Rp390.00 | x |
| 2023-12-31 | Rp297.37 | Rp390.00 | x |
| 2024-12-31 | Rp339.77 | Rp390.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Itama Ranoraya utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.40%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.45%
- • Asset Turnover: 0.59x
- • Equity Multiplier: 3.24x
- Recent ROE (10.40%) is below the historical average (21.32%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 6.56% | 5.44% | 0.48x | 2.52x | Rp-371.37 Million |
| 2017 | 54.06% | 10.65% | 1.76x | 2.88x | Rp19.54 Billion |
| 2018 | 48.41% | 12.15% | 1.95x | 2.04x | Rp25.60 Billion |
| 2019 | 14.12% | 11.79% | 0.87x | 1.38x | Rp9.69 Billion |
| 2020 | 24.97% | 10.73% | 1.05x | 2.21x | Rp36.29 Billion |
| 2021 | 22.34% | 8.50% | 1.69x | 1.56x | Rp61.95 Billion |
| 2022 | 9.92% | 6.37% | 1.03x | 1.52x | Rp-399.81 Million |
| 2023 | 1.13% | 0.75% | 0.66x | 2.31x | Rp-40.72 Billion |
| 2024 | 10.40% | 5.45% | 0.59x | 3.24x | Rp2.03 Billion |
Industry Comparison
This section compares Itama Ranoraya's net assets metrics with peer companies in the Medical Distribution industry.
Industry Context
- Industry: Medical Distribution
- Average net assets among peers: $1,556,838,962,962
- Average return on equity (ROE) among peers: 7.59%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Itama Ranoraya (IRRA) | Rp556.81 Billion | 6.56% | 3.89x | $4.89 Million |
| Enseval Putra Megatrading Tbk (EPMT) | $5.13 Trillion | 10.09% | 0.45x | $31.13 Million |
| Kimia Farma Persero Tbk (KAEF) | $947.76 Billion | 5.84% | 0.53x | $16.65 Million |
| PT Medela Potentia Tbk (MDLA) | $1.71 Trillion | 18.29% | 1.59x | $130.48 |
| Millennium Pharmacon International (SDPC) | $282.50 Billion | 5.99% | 5.27x | $1.76 Million |
| PT Soho Global Health Tbk (SOHO) | $1.21 Trillion | 4.10% | 1.31x | $138.50 Million |
| Dosni Roha Indonesia Tbk PT (ZBRA) | $69.73 Billion | 1.21% | 0.95x | $1.64 Million |